GlassScriptPhysician profile
Leanne M Camisa
NPI 1124081377
$2,724.90
in general payments reported to CMS, 2019-2025
31 companies · $246 in 2025
The $246 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $671 · 2020: $423 · 2021: $73.39 · 2022: $384 · 2023: $570 · 2024: $358 · 2025: $246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,173.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $562.18 | 2019-2025 | Shingrix, Arexvy |
| Abbott Laboratories | $440.27 | 2022-2025 | Freestyle Libre 3, Proclaim, Freestyle Libre 2 |
| Amgen INC. | $312.41 | 2019-2025 | Evenity, Prolia |
| Exact Sciences Corporation | $182.86 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $174.23 | 2020-2024 | Breztri, Andexxa |
| Merck Sharp & Dohme LLC | $138.73 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.43 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $92.42 | 2022 | |
| Pfizer INC. | $92.18 | 2019-2024 | |
| Astellas Pharma US INC | $90.94 | 2019-2020 | |
| Lilly USA, LLC | $56.67 | 2019-2022 | |
| Sanofi Pasteur INC. | $54.71 | 2019-2022 | |
| Novo Nordisk INC | $48.81 | 2019 | |
| Organogenesis INC. | $36.34 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $33.04 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $31.96 | 2020 | |
| Sanofi-Aventis U.S. LLC | $27.96 | 2019 | |
| Daiichi Sankyo INC. | $27.64 | 2019 | |
| Ibsa Pharma INC. | $24.05 | 2020 | |
| Organon LLC | $23.14 | 2022-2023 | Nexplanon |
| Biohaven Pharmaceutical Holding Company LTD. | $22.45 | 2022 | |
| Collegium Pharmaceutical, INC. | $17.92 | 2020 | |
| Circassia INC. | $17.06 | 2019 | |
| Radius Health, INC. | $16.15 | 2019 | |
| Edwards Lifesciences Corporation | $16.11 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Medtronic, INC. | $15.96 | 2024 | Intellis Adaptivestim |
| Mylan Specialty L.P. | $15.43 | 2019 | |
| Bausch Health US, LLC | $15.34 | 2020 | |
| Eisai INC. | $15.28 | 2020 | |
| Janssen Pharmaceuticals, INC | $13.51 | 2019 | |
| Biogen, INC. | $12.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leanne Camisa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.